Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emerald Health Therapeutics Inc TBQBF


Primary Symbol: EMHTF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and production excellence.


OTCQB:EMHTF - Post by User

Emerald Health Therapeutics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by MoneyMaker90820on Dec 08, 2017 1:33am
387 Views
Post# 27115216

EMH Facts, not pumping or bashing . My DD

EMH Facts, not pumping or bashing . My DDThe Team behind Emerald Health Therapeutics 


Bin Huang, PhD, MBA President & CEO 20+ years in life sciences including 15 years as CEO

Avtar Dhillon, MD Executive Chairman Chairman of 5 public life science companies, led turnaround of  NASDAQ:INO from $10m to $1b company

Traviss Graham VP Production 15+ years in cannabis production, processing, and product development

Sandra Pratt, CPA, CA CFO 20+ years in accounting & finance Angiotech Pharmaceuticals
 

Peer comparison

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities